Analysis · Global
THC and CBD for Dementia Agitation: What the LiBBY Trial Actually Found
A controlled trial found that a precise THC/CBD formulation reduced agitation in advanced dementia. The result deserves attention—and careful limits.
Global
Cannabis reform movements and international policy developments worldwide.
Analysis · Global
Brazil’s New Medical Cannabis Rules Choose Access With Conditions
Brazil’s regulator has clarified a revised pathway for manufacturing and importing medical cannabis products. The model protects access, but keeps the category deliberately temporary.
Analysis · Global
The RESONANCE Trial Asks a Better Question About Cannabis and Cancer
A newly published trial protocol will test whether medicinal cannabis improves quality of life and symptom control in advanced cancer. It is promising research, not a result.
Analysis · Global
The Environmental Cost of Cannabis Cultivation
As the global cannabis industry expands, so does its environmental footprint. Indoor cultivation is energy-intensive, water use is high, and packaging waste is mounting. Can the industry's growth be reconciled with its environmental responsibilities?
Analysis · Global
Cannabis and Sleep: What the Research Actually Shows
Sleep disturbance is one of the most common reasons patients cite for using medical cannabis. The research paints a complex picture: cannabis can help you fall asleep faster, but it may also alter sleep architecture in ways that matter.
Analysis · Global
Beyond THC and CBD: The Minor Cannabinoids Reshaping Medicine
THC and CBD dominate the conversation, but cannabis contains over 100 cannabinoids. CBG, CBN, CBC, and THCV are emerging as therapeutic compounds in their own right. Here's what the research tells us so far.
Analysis · Global
Global Cannabis Reform Roundup: Policy Changes Across the World
From Germany to Brazil, the global cannabis reform landscape is shifting rapidly. A roundup of the major policy developments you need to know.
Analysis · Global
Key Cannabinoid Research Studies to Watch in 2026
From pain management to mental health, the clinical research pipeline for cannabinoid medicines is more active than ever. Here are the studies to watch.
Analysis · Global
CBD for Anxiety: Promise Is Still Running Ahead of Proof
Clinical research offers encouraging signals, but different conditions, doses and study designs make broad claims about CBD and anxiety premature.
Analysis · Global
THC and Chronic Pain: The Evidence Is Growing, but the Caveats Matter
THC-based medicines may help some people with chronic pain, but variable benefits, side effects and limited long-term data demand a measured reading.
Analysis · Global
Beyond THC and CBD: The Emerging Science of Terpenes
Terpenes — the aromatic compounds in cannabis — are emerging as a key area of research with potential therapeutic applications.